ALESSANDRO GONCALVES CAMPOLINA

(Fonte: Lattes)
Índice h a partir de 2011
8
Lattes
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina
LIM/24 - Laboratório de Oncologia Experimental, Hospital das Clínicas, Faculdade de Medicina - Líder

Filtros

Limpar filtros

Configurações

Assunto: Health Care Sciences & Services ×

Resultados de Busca

Agora exibindo 1 - 10 de 24
  • conferenceObject
  • article 7 Citação(ões) na Scopus
    Palliative cancer care: costs in a Brazilian quaternary hospital
    (2022) ROZMAN, Luciana Martins; CAMPOLINA, Alessandro Goncalves; LOPEZ, Rossana Mendoza; CHIBA, Toshio; SOAREZ, Patricia Coelho De
    Palliative care (PC) improves the quality of life of patients with diseases such as cancer, and several studies have shown a reduction in costs among patients who use PC services when compared with those receiving standard oncological treatments. Most studies on PC costs are carried out in high-income countries. There is a lack of these types of studies in middle-income and low-income countries and of better evidence about this intervention. Objective To describe resource utilisation and costs among patients with cancer in a Brazilian quaternary hospital by cancer localisation and per month of treatment before death. Methods This study is a description of retrospective costs to estimate the costs of formal healthcare sector associated with PCs, from the perspective of a public quaternary cancer hospital. Unit costs were estimated using microcosting and macrocosting approaches. Setting/Participants Patients older than 18 years old who died from 2010 to 2013 and who had at least two visits in PC and/or made use of hospice care. Results Among the 2985 patients included in the study, the average cost per patient was US$12 335, ranging from US$8269 for patients with pancreatic cancer to US$19 395 for patients with brain cancer. The main costing item was hospital admission (47.6% of the total cost), followed by hospice care (29.5%) and medical and other supplies (11.1%). Conclusions The study clarified the direct medical costs and the profile and use of resources of patients with cancer who need PC, and can help in the planning and allocation of resources in cancer care.
  • conferenceObject
    SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS IN CANCEROLOGY IN BRAZIL BETWEEN 1980 AND 2013
    (2014) YUBA, T. Y.; DECIMONI, T. C.; LEANDRO, R.; CAMPOLINA, A. G.; SOAREZ, P.
  • article 1 Citação(ões) na Scopus
    Cost-effectiveness analysis of trastuzumab for early breast cancer in Brazil
    (2022) BOTELHO, Carlos Henrique; ESTEVEZ-DIZ, Maria Del Pilar; CAMPOLINA, Alessandro Goncalves
    Background: Adjuvant chemotherapy with trastuzumab for HER2 positive breast cancers has brought considerable benefits to disease-free survival and overall survival. Objective: To conduct a cost-effectiveness analysis of the treatment of patients with early and locally advanced HER2 positive breast cancer, within the scope of the Brazilian public health system, comparing adjuvant chemotherapy with and without trastuzumab, for 1 year of treatment. Methods: A 4-state Markov model was developed to estimate strategy costs and outcomes. Results: Based on the proposed model, we verified an incremental benefit of trastuzumab therapy compared to treatment without trastuzumab with 0.84 quality-adjusted life years (QALY) and 1.16 life years gained (LYG). The use of adjuvant chemotherapy with trastuzumab has an ICER of US$19,599.26 for each quality-adjusted life year and US$14,180.68 for each life year gained in relation to chemotherapy without trastuzumab. Conclusion: In Brazil, adjuvant chemotherapy with trastuzumab may be considered cost-effective only if a cost-effectiveness threshold is stipulated with the value starting at three times the Brazilian GDP per capita for QALY or two times the Brazilian GDP per capita for LYG, from health system perspective.
  • conferenceObject
    ECONOMIC ANALYSIS OF HEPATO CELLULAR CARCINOMA TREATMENT BY SEVERITY OF DISEASE
    (2017) TANI, J. A.; CAMPOLINA, A. G.; DECIMONI, T. C.; TOMITAO, M.; FERREIRA, L. A.
  • conferenceObject
    COMPARISON OF TREATMENTS FOR CANCER OF HEAD AND NECK ADJUSTED BY INCLINATION SCORE: RADIOTHERAPY VERSUS SURGERY plus RADIOTHERAPY
    (2015) CAMPOLINA, A. G.; COSTA, A.; LEANDRO, R. F.; V, R. Lopez; SOAREZ, P. C.
  • article 13 Citação(ões) na Scopus
    Early Palliative Care and Its Impact on End-of-Life Care for Cancer Patients in Brazil
    (2018) ROZMAN, Luciana Martins; CAMPOLINA, Alessandro Goncalves; LOPEZ, Rossana Veronica Mendonca; KOBAYASHI, Silvia Takanohashi; CHIBA, Toshio; SOAREZ, Patricia Coelho de
    Background: Integrating palliative care into standard oncology care has been recommended for cancer patients. Early palliative care is associated with less aggressive treatment at the end of life. Objective: To describe cancer patients receiving palliative care in Brazil, determining the time from entry into palliative care to death, and investigating whether late referral to palliative care is associated with aggressive end-of-life treatment. Design: This was a cross-sectional study of cancer patients receiving palliative care in Brazil. Setting/Subjects: Subjects were 2985 cancer patients 18 years of age who received at least two palliative care visits at the SAo Paulo State Cancer Institute, in the city of SAo Paulo, Brazil, and died between 2010 and 2013. Measurements: We evaluated the time from the first palliative care consult to death, stratifying cases by the timing of entry into palliative care (3 or <3 months before death). The associations between early palliative care and indicators of aggressive treatment were assessed by Pearson's chi-square test and Fisher's exact test. Results: The overall median time between entry into palliative care and death was 34 days (mean, 72 days) and was significantly shorter in 2013 than in 2010 (p<0.001). The number of emergency department visits was significantly lower among the patients who entered palliative care earlier (p<0.001). Conclusions: Among cancer patients in Brazil, late referral to palliative care is common. Patients who enter palliative care earlier appear to receive less aggressive end-of-life treatment.
  • conferenceObject
    EVALUATION OF AN INTEGRATED CARE PATHWAY FOR RECTAL CANCER TREATMENT IMPLEMENTATION USING A LOGIC MODEL
    (2016) KOBAYASHI, S. T.; CAMPOLINA, A. G.; SOAREZ, P. C.; JR, U. Ribeiro; DIZ, M. D.; HOFF, P. M.
  • conferenceObject
    COST-EFFECTIVENESS ANALYSIS OF ON-PUMP AND OFF-PUMP STABLE MULTIVESSEL CORONARY ARTERY BYPASS GRAFTINGA angstrom MASS III 5-YEAR FOLLOW-UP
    (2016) SCUDELER, T. L.; HUEB, W.; SOAREZ, P. C. de; CAMPOLINA, A. G.; HUEB, A. C.; REZENDE, P. C.; LIMA, E. G.; GARZILLO, C. L.; COSTA, L. M.; OIKAWA, F. T.; RAMIRES, J. A.; KALIL FILHO, R.
  • article 3 Citação(ões) na Scopus
    Factors Associated with the Costs of Palliative Care: A Retrospective Cost Analysis at a University Cancer Hospital in Brazil
    (2021) ROZMAN, Luciana Martins; CAMPOLINA, Alessandro Goncalves; PATINO, Elizabeth Gonzalez; SOAREZ, Patricia Coelho de
    Background: There have been few studies evaluating the costs of palliative care (PC) in low- and middle-income countries (LMICs), especially for patients with cancer. Objectives: The objective of this study was to identify the sociodemographic and clinical variables that could explain the cost per day of PC for cancer in Brazil. Methods: This was a retrospective cost analysis of PC at a quaternary cancer center in Sao Paulo, Brazil, between January 2010 and December 2013. Factors influencing the cost per day were assessed with generalized linear models and generalized linear-mixed models in which the random effect was the site of the cancer. Results: The study included 2985 patients. The mean total cost per patient was $12,335 (standard deviation [SD] = 14,602; 95% confidence interval [CI] = 11,803 to 12,851). The mean cost per day per patient was $325.50 (SD = 246.30, 95% CI = 316.60 to 334.30). There were statistically significant differences among cancer sites in terms of the mean cost per day. Multivariate analysis revealed that the drivers of cost per day were Karnofsky performance status, the number of hospital admissions, referral to PC, and place of death. Place of death had the greatest impact on the cost per day; death in a hospital and in hospice care increased the mean cost per day by $1.56 and $1.83, respectively. Conclusion: To allocate resources effectively, PC centers in LMICs should emphasize early enrollment of patients at PC outpatient clinics, to avoid hospital readmission, as well as advance planning of the place of death.